Ascletis Pharma

Performance

About Ascletis Pharma

Ascletis Pharma is a biotechnology company focused on the development and commercialization of therapeutics for metabolic and related diseases. It employs proprietary AI-assisted structure-based drug discovery (AISBDD) and an Ultra-Long-Acting Platform (ULAP) along with Peptide Oral Transport ENhancement Technology (POTENT) to create both small molecules and peptides, including lead programs for chronic weight management. The company conducts research and development with in-house drug candidates such as ASC30, ASC36, ASC35, and ASC37, and is listed on the Hong Kong Stock Exchange (1672.HK).